8-K filing — LeonaBio, Inc. (LONA)
Filed: 2026-09-22 AccNo: 0001193125-26-397952 Size: 154 KB Item 8.01: Other Events
Stocks · News reference
LeonaBio’s Lead Product Candidate, Lasofoxifene, To Be Featured In Multiple Presentations At Dava Oncology’s 4th Summit On Breast Cancer
LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that its lead product candidate,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
LeonaBio Enrolls 500th Subject In Phase 3 ELAINE-3 Trial For Lasofoxifene With Abemaciclib
On August 26, 2026, LeonaBio, Inc. (the "Company") announced that it had enrolled the 500th subject in its ongoing Phase 3 ELAINE-3 clinical trial (NCT05696626) for lasofoxifene in combination with abemaciclib,
Mizuho Maintains Outperform on LeonaBio, Lowers Price Target to $15
Mizuho analyst Graig Suvannavejh maintains LeonaBio (NASDAQ:LONA) with a Outperform and lowers the price target from $16 to $15.
Citizens Maintains Market Outperform on LeonaBio, Lowers Price Target to $17
Citizens analyst Jason N. Butler maintains LeonaBio (NASDAQ:LONA) with a Market Outperform and lowers the price target from $18 to $17.